Infinity Pharmaceuticals | INFI


Peers Price Chg Day Year Date
Eisai 5,322.00 185.00 3.60% -7.02% Sep/08
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 11,963.00 -127.00 -1.05% -5.89% Sep/08
Bristol-Myers Squibb 47.26 0.12 0.25% -2.58% Sep/08
Clal Biotechnology 32.00 0.40 1.27% -17.53% Sep/04
Compugen 479.60 -2.50 -0.52% -33.09% Sep/04
Cipla 1,544.40 -9.00 -0.58% -4.68% Sep/08
CSL 213.37 4.12 1.97% -28.97% Sep/08
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Grifols 10.13 0.23 2.32% 19.32% Sep/05
GlaxoSmithKline 1,464.00 -12.00 -0.81% -11.99% Sep/08
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Novartis 102.57 -1.41 -1.36% 2.98% Sep/08
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Roche Holding 270.50 -3.70 -1.35% 1.24% Sep/08
TG Therapeutics 32.21 0.32 1.00% 46.21% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Infinity Pharmaceuticals traded at $0 this Monday April 8th. Looking back, over the last four weeks, Infinity Pharmaceuticals lost 0 percent. Over the last 12 months, its price fell by 100.00 percent. Looking ahead, we forecast Infinity Pharmaceuticals to be priced at 0 by the end of this quarter and at 0 in one year, according to Trading Economics global macro models projections and analysts expectations.

Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for people with cancer. It is also focusing on advancing, eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its pipeline includes MARIO-275 is, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line setting for triple negative breast cancer (TNBC), and front-line renal cell carcinoma (RCC). MARIO-1 is in Phase I /1b clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity for eganelisib.